TXMD (TherapeuticsMD) Accounts Payable: $0.02 Mil (As of Mar. 2026)


TXMD TherapeuticsMD Inc TXMD
55 GF Score
Price $1.97
GF Value $2.05
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is TherapeuticsMD Accounts Payable?

TherapeuticsMD TXMD +0.51% 55 Accounts Payable is $0.02 Mil as of Mar. 2026. GuruFocus rates TXMD with a GF Score™ of 55/100 and a GF Value™ of $2.05 (Fairly Valued). The stock has 3 warning signs investors should review.

TherapeuticsMD's Accounts Payable for the quarter that ended in Mar. 2026 was $0.02 Mil.

TherapeuticsMD's quarterly Accounts Payable increased from Sep. 2025 ($0.26 Mil) to Dec. 2025 ($0.38 Mil) but then declined from Dec. 2025 ($0.38 Mil) to Mar. 2026 ($0.02 Mil).

TherapeuticsMD's annual Accounts Payable increased from Dec. 2023 ($0.03 Mil) to Dec. 2024 ($0.26 Mil) and increased from Dec. 2024 ($0.26 Mil) to Dec. 2025 ($0.38 Mil).

TherapeuticsMD Accounts Payable Related Terms

TherapeuticsMD Accounts Payable Historical Data

* Premium members only.

The historical data trend for TherapeuticsMD's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TherapeuticsMD Accounts Payable Chart

TherapeuticsMD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.37 2.16 0.03 0.26 0.38

TherapeuticsMD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.35 0.26 0.38 0.02
TXMD
55GF Score
TherapeuticsMD Inc TXMD
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TherapeuticsMD Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.02 Mil mean?
TherapeuticsMD (TXMD) has a Accounts Payable of $0.02 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on TherapeuticsMD and its competitors.
Is TherapeuticsMD's Accounts Payable too high?
TherapeuticsMD's current Accounts Payable is $0.02 Mil. Overall, TherapeuticsMD has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TherapeuticsMD's Accounts Payable compare to CPHI and RMTI?
TherapeuticsMD's Accounts Payable of $0.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on TherapeuticsMD and its competitors. TherapeuticsMD's current Accounts Payable is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TherapeuticsMD stock overvalued right now?
Based on GuruFocus' analysis, TherapeuticsMD (TXMD) is currently considered Fairly Valued. The stock's GF Value™ is $2.05, compared to a current price of $1.97 — trading 3.9% below its estimated fair value. The current Accounts Payable is $0.02 Mil. TherapeuticsMD's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For TherapeuticsMD (TXMD), the current Accounts Payable is $0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TherapeuticsMD (TXMD) Overvalued in 2026?

Based on GuruFocus' analysis, TherapeuticsMD stock appears to be undervalued. The current stock price of $1.97 is trading 3.9% below its estimated GF Value™ of $2.05. GuruFocus considers TherapeuticsMD to be Fairly Valued.

Key valuation signals for TXMD:

  • Accounts Payable: $0.02 Mil
  • GF Value™: $2.05 vs. price of $1.97 (3.9% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the TXMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TherapeuticsMD Business Description

Other Exchanges 29TA:Germany
Address 951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
55GF Score

Get the complete analysis for TXMD

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.97
Price
$2.05
GF Value